📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Zelluna

1.1 - Company Overview

Zelluna Logo

Zelluna

Headquarter: Norway
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of TCR-based immunotherapies, developing off-the-shelf TCR-guided NK cell therapies for solid tumors. Pipeline includes a MAGE-A4 TCR-NK therapy for cancer advancing toward clinical trials, leveraging a wide range of TCRs.

Products and services

  • TCR-based Immunotherapy Development: Zelluna architects therapies leveraging a wide range of TCRs to develop TCR-based treatments addressing diverse cancer types and patients
  • MAGE-A4 TCR-NK Cell Therapy: Zelluna develops a target-specific TCR-NK product that recognizes MAGE-A4 to treat cancer, advancing towards clinical trials
  • TCR-NK Cell Therapies: Privately owned Norwegian biopharmaceutical company Zelluna Immunotherapy engineers off-the-shelf, TCR-guided NK cell therapies aimed at treating solid tumors

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Zelluna

CO.DON Logo

CO.DON

HQ: Germany Website
  • Description: Provider of autologous cell therapies and cell cultivation for regenerative treatment of articular cartilage and spinal disc defects worldwide, developing, producing, and marketing minimally invasive solutions to repair knee joint cartilage damage from traumatic or degenerative defects, including matrix-associated autologous chondrocyte transplantation (M-ACT).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full CO.DON company profile →
Amorcyte Logo

Amorcyte

HQ: United States Website
  • Description: Provider of cell therapy products for cardiovascular disease, including lead candidate AMR—001 to prevent major adverse cardiac events following acute myocardial infarction (AMI); Phase I clinical trials have demonstrated feasibility, safety and biologic activity.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Amorcyte company profile →
Creative Medical Technology Logo

Creative Medical Technology

HQ: United States Website
  • Description: Provider of regenerative and cell therapy platforms in immunology, urology, neurology, and orthopedics, including ImmCelzTM autologous immune cell therapy; Enhanced Allogenic Platform using perinatal tissue cells; Supercharged Autologous Immunotherapy; Reprogrammed Cell Therapy with iPSCs; Rapid Autologous Therapies, and CaverStem for erectile dysfunction.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Creative Medical Technology company profile →
ImmunityBio Logo

ImmunityBio

HQ: United States Website
  • Description: Provider of clinical-stage immunotherapy solutions focused on harnessing the immune system to treat disease.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full ImmunityBio company profile →
BioSenic Logo

BioSenic

HQ: Belgium Website
  • Description: Provider of biopharmaceutical and cell therapy products for bone and osteo-articular diseases, offering ALLOB for bone regeneration; JTA-004 for knee osteoarthritis pain; ArsciCor, an oral arsenic trioxide formulation for chronic graft versus host disease; and ArsciMed, an intravenous arsenic trioxide treatment for autoimmune diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full BioSenic company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Zelluna

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Zelluna

2.2 - Growth funds investing in similar companies to Zelluna

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Zelluna

4.2 - Public trading comparable groups for Zelluna

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Zelluna

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Zelluna

What does Zelluna do?

Zelluna is a provider of TCR-based immunotherapies, developing off-the-shelf TCR-guided NK cell therapies for solid tumors. Pipeline includes a MAGE-A4 TCR-NK therapy for cancer advancing toward clinical trials, leveraging a wide range of TCRs.

Who are Zelluna's competitors?

Zelluna's competitors and similar companies include CO.DON, Amorcyte, Creative Medical Technology, ImmunityBio, and BioSenic.

Where is Zelluna headquartered?

Zelluna is headquartered in Norway.

How many employees does Zelluna have?

Zelluna has 1,000 employees 🔒.

When was Zelluna founded?

Zelluna was founded in 2010 🔒.

What sector and industry vertical is Zelluna in?

Zelluna is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Zelluna

Who are the top strategic acquirers in Zelluna's sector and industry

Top strategic M&A buyers and acquirers in Zelluna's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Zelluna?

Top strategic M&A buyers groups and sectors for Zelluna include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Zelluna's sector and industry vertical

Which are the top PE firms investing in Zelluna's sector and industry vertical?

Top PE firms investing in Zelluna's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Zelluna's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Zelluna's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Zelluna's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Zelluna include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Zelluna's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Zelluna?

The key public trading comparables and valuation benchmarks for Zelluna include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Zelluna for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Zelluna with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Zelluna's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Zelluna with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Zelluna's' sector and industry vertical?

Access recent funding rounds and capital raises in Zelluna's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Zelluna